

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



四环医药  
*SihuanPharm*

## **Sihuan Pharmaceutical Holdings Group Ltd.**

四環醫藥控股集團有限公司

*(incorporated in Bermuda with limited liability)*

**(Stock Code: 0460)**

### **VOLUNTARY ANNOUNCEMENT XUANZHU BIOPHARM AND INNOBIC REACHED A COMMERCIAL COOPERATION FOR BIREOCICLIB IN THE THAILAND MARKET**

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Xuanzhu Biopharmaceutical Co., Ltd. (“**Xuanzhu Biopharm**”, stock code: 02575.HK), a non wholly-owned subsidiary of the Group, has recently entered into a tri-party commercial agreement (the “**Agreement**”) in respect of Bireociclib Tablets (the “**Target Product**”) with Innobic (Asia) Co., Ltd. (“**Innobic (Asia)**”), a Thai pharmaceutical company, and ZaoAn International Trading Co., Ltd (“**ZaoAn International**”) with a term expiring on 30 June 2036.

Pursuant to the Agreement, Xuanzhu Biopharm jointly grants Innobic (Asia) and ZaoAn International exclusive commercialisation rights for the Target Product within the territory of Thailand (the “**Target Territory**”). The commercialisation rights include the rights to import, promote, market, offer for sale, sell and distribute the Target Product in the Target Territory. Innobic (Asia) will act as the distributor and be responsible for pharmaceutical registration, local marketing and commercial operation of the Target Product in the Target Territory. Under the Agreement, the marketing authorisation for the Target Product will be held in the name of Innobic (Asia). ZaoAn International will act as the intermediary and assume primary payment obligations under purchase orders. Xuanzhu Biopharm will supply the Target Product at the agreed supply prices to support the commercialisation activities of the Target Product in the Target Territory.

The Agreement provides for certain minimum purchase quantities on an annual basis, and licence fees payable by Innobic (Asia) to Xuanzhu Biopharm upon signing and upon obtaining marketing authorisation from the Thai Food and Drug Administration (TFDA). Innobic (Asia) and ZaoAn International are jointly and severally liable to Xuanzhu Biopharm for their respective obligations under the Agreement.

This strategic cooperation is implemented in Thailand, one of the core member economies of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). By leveraging international partners to expand overseas markets, Xuanzhu Biopharm will continuously expand the influence of its products across the promising Southeast Asian market, bring economic benefits to Xuanzhu Biopharm and the Group, and enhance the brand value of Xuanzhu Biopharm and the Group.

Please refer to the “Commercial Cooperation with Innobic for Bireociclib in the Thailand Market” announcement released by Xuanzhu Biopharm on 3 September 2026 for details of Bireociclib, Innobic (Asia), and ZaoAn International.

## **IMPLICATIONS UNDER THE LISTING RULES**

As the transactions contemplated under the tri-party commercial agreement are revenue-generating transactions entered into in the ordinary and usual course of business of Xuanzhu Biopharm and Sihuan Pharmaceutical, the entry into such tri-party commercial agreement does not constitute a notifiable transaction under Chapter 14 of the Listing Rules.

## **ABOUT XUANZHU BIOPHARM**

Xuanzhu Biopharm was listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2025 (stock code: 02575.HK). It is an innovative pharmaceutical enterprise rooted in China with a global-minded vision. Focusing on major disease areas including digestion, oncology and metabolism, the company is committed to the research and development (“R&D”), production and commercialisation of Class 1 new drugs with core independent intellectual property rights. As a R&D-driven commercial-stage biotech innovator empowered by AI, the company has built a synergistic technical system integrating small-molecule drug R&D platforms, biologic drug R&D platforms and AI-driven drug discovery platforms. This enables it to maintain one of the rare domestic product pipelines covering multiple modalities such as small-molecule chemicals, large-molecule biologics and antibody-drug conjugates (ADCs). Guided by unmet clinical needs, the company strives to evolve into a first-class innovative pharmaceutical enterprise with in-house capabilities for research-and-development, manufacturing and sales.

## **ABOUT SIHUAN PHARMACEUTICAL**

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetics and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group’s latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board  
**Sihuan Pharmaceutical Holdings Group Ltd.**  
**Dr. Che Fengsheng**  
*Chairman and Executive Director*

Hong Kong, 3 September 2026

*As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong and Ms. Chen Yanling; the non-executive director of the Company is Mr. Che Yuxuan; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.*